Abstract

Background: Active Pharmaceutical Ingredient (API) manufacturing is an important segment of the Indian pharma industry. India ranks third in terms of volume of medicines produced, and is a major global supplier of generic medicines. However, India depends heavily on the import of several raw materials used to produce some of these medicines. Main Body: This paper highlights how the situation emerged, as well as the various steps taken by the government to reduce import dependency and promote domestic manufacturing of APIs. Through various consultations with government officials, policy analysts and academicians, and interactions with key industry experts, the paper also highlights the public health perspectives of such dependence, especially regarding the secure access to essential medicines. India needs a conducive ecosystem to capitalize on the full potential of its API manufacturing capabilities, which may require some short-term and some mid/long-term interventions. Conclusions: It concludes by providing certain short-, medium- and long-term recommendations in the policy, fiscal and technology domains, to promote API independence. It also summarizes the various steps taken by the government in moving towards domestic manufacturing of APIs.

Highlights

  • India has today emerged as the “Pharmacy of the Global South”, with its pharmaceutical industry ranking third largest in the world in terms of medicines produced by volume

  • India accounts for 20% of global generic medicine exports by volume and supplies over 50% of global demand for vaccines (Indian Pharmaceutical Alliance 2019)

  • A National Consultation meeting of Indian Council of Medical Research (ICMR) with Pharmaceutical Industry was held on 17 July 2019, with participation from various stakeholders, including National Institution for Transforming India (NITI) Aayog, Department of Pharmaceuticals (DoP), Drug Controller General of India (DCGI), National Pharmaceutical Pricing Authority (NPPA), industry experts, policy analysts and academicians

Read more

Summary

Introduction

India has today emerged as the “Pharmacy of the Global South”, with its pharmaceutical industry ranking third largest in the world in terms of medicines produced by volume. India accounts for 20% of global generic medicine exports by volume and supplies over 50% of global demand for vaccines (Indian Pharmaceutical Alliance 2019). Despite all of these achievements, the Indian pharmaceutical industry has, over the years, become significantly dependent on import of the basic raw materials that are used to produce the Finished Dosage Formulations. China’s share of imports stands at around 60% (Minister of Commerce and Industry, Department of Commerce, Government of India 2019) This import dependence of API and intermediates is high for many of the low-value, high-volume and off-patent essential medicines that are used widely by the Indian population (Figure 2). The overall objective was to find ways to improve availability of essential medicines in India, with special emphasis on self-reliance

Methodology
Case Study of Pen-G
Public Health and Medicine Security
Current Understanding and Gaps in Information
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call